If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET. A webcast and subsequent archived replay of the fir ...

财务信息更新 - EyePoint Pharmaceuticals, Inc. 在2025年1月13日发布了截至2024年12月31日的财务信息更新[6] 临床计划与成就 - 公司发布了2025年临床计划并强调了近期的企业和临床成就[7] 投资者演示文稿与新闻稿 - 投资者演示文稿和新闻稿已作为附件提交，并纳入8-K表格的参考[8]

– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors – – Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – – Presenting at the 43rd Annual J.P. Morgan Healthcare ...

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. “I am pleased to welcome Dr. Sanders to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. “Scient ...

WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. A webcast and subseque ...

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expres ...

Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.56 indicates a potential upside of 175.1%.The average comprises nine short-term price targets ranging from a low of $18 to a high of $68, with a standard deviation of $15.13. While the lowest estimat ...

现金及资金状况 - 2024年9月30日现金、现金等价物和有价证券投资为2.538亿美元[101] - 2024年10月股权融资净收益1.61亿美元[101] - 这些资金可支持公司运营至2027年[101] 不同时期的收入情况 - 2024年三季度产品销售净额较2023年同期减少19%为664美元[114] - 2024年三季度许可和合作协议收入较2023年同期减少32%为9561美元[114] - 2024年三季度特许权使用费收入较2023年同期增加20%为299美元[114] - 截至2024年9月30日的九个月，产品销售净额降低11.1百万美元降幅82%至2.4百万美元[124] - 截至2024年9月30日的九个月，许可和合作协议收入增加10.1百万美元涨幅57%至27.9百万美元[125] 不同时期的费用情况 - 2024年三季度研发费用较2023年同期增加70%为29542美元[114] - 2024年三季度销售和营销费用较2023年同期减少95%为24美元[114] - 2024年三季度总务和管理费用较2023年同期增加23%为12970美元[114] - 截至2024年9月30日的三个月，销售成本（不含收购无形资产摊销）降低0.5百万美元降幅39%至0.7百万美元[118] - 截至2024年9月30日的三个月，研发费用增加12.2百万美元涨幅70%至29.5百万美元[119] - 截至2024年9月30日的三个月，销售和营销费用降低0.5百万美元降幅95%[120] - 截至2024年9月30日的三个月，一般和管理费用增加2.4百万美元涨幅23%至13.0百万美元[121] - 截至2024年9月30日的九个月，研发费用增加42.8百万美元涨幅92%至89.6百万美元[128] - 截至2024年9月30日的九个月，销售和营销费用降低11.4百万美元降幅99%至0.1百万美元[129] - 截至2024年9月30日的九个月，一般和管理费用增加10.9百万美元涨幅38%至39.8百万美元[130] 不同时期的净亏损情况 - 2024年三季度净亏损较2023年同期增加133%为29361美元[114] - 2024年前九个月经营活动现金流出9040万美元净亏损8950万美元非现金费用2580万美元[139] - 2023年前九个月经营活动现金流入2500万美元净亏损5670万美元非现金费用1050万美元[140] 不同时期的现金流量变化情况 - 2024年前九个月1.197亿美元净现金用于购买有价证券370万美元用于购买固定资产和设备[141] - 2023年前九个月销售有价证券提供4640万美元净现金260万美元用于购买固定资产和设备[141] - 2024年前九个月融资活动提供净现金1230万美元[142] - 2023年前九个月融资活动使用净现金3140万美元[142] - 2024年经营活动现金流量变化为减少1.15361亿美元[139] - 2024年投资活动现金流量变化为减少1.67226亿美元[139] - 2024年融资活动现金流量变化为增加4375.2万美元[139] 递延收入情况 - 2024年与ANI的许可协议相关的递延收入为2210万美元[139]

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.55 per share when it actually produced a loss of $0.58, delivering a surprise of -5.45%.Over the last four ...